TTY Biopharm to sell Aplidin in Taiwan for PharmaMar
Executive Summary
TTY Biopharm Co. Ltd. licensed exclusive rights to sell PharmaMar SA’s Aplidin (plitidepsin) in Taiwan for blood cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice